^
Association details:
| Biomarker: | NF1 mutation |
|---|---|
| Cancer: | Lung Cancer |
| Drug: | Mekinist (trametinib) (MEK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Trametinib in Patients With Advanced Neurofibromatosis Type 1 (NF1)-Mutant Non-small Cell Lung Cancer
Excerpt:
...Documented non-synonymous somatic mutation in NF1 in any tumor specimen or cell-free DNA assay by Clinical Laboratory Improvement Amendments (CLIA)-approved laboratory....
Trial ID:
Source:
Title:
Trametinib in Patients With NF1-, GNAQ-, or GNA11-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2
Published date:
04/04/2023
Excerpt:
Trametinib was administered at 2 mg once daily over 28-day cycles until toxicity or disease progression....46 with NF1 mutations (S1) and four with GNA11 mutations (S2)….All in S2 had nonuveal melanoma and GNA11 Q209L variant....Two partial responses (PR) were noted in S1, one patient each with advanced lung cancer and GBM for an ORR of 4.3% (90% CI, 0.8 to 13.1)….One patient with melanoma in S2 had a PR (ORR, 25%; 90% CI, 1.3 to 75.1). Prolonged stable disease (SD) was also noted in five patients (four in S1 and one in S2) with additional rare histologies.
DOI:
10.1200/PO.22.00421
Trial ID:
